Black Diamond Therapeutics (BDTX) Non-Current Assets (2018 - 2026)

Black Diamond Therapeutics (BDTX) has reported Non-Current Assets for 9 consecutive years, with $9.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Non-Current Assets fell 50.99% year-over-year to $9.6 million; the trailing twelve-month figure through Jun 2026 stood at $48.9 million (down 41.82% YoY), and the FY2025 full-year result was $10.6 million, down 50.75% from the prior year.
• Non-Current Assets retreated to $9.6 million in Q2 2026 per BDTX's latest filing, from $10.0 million in the prior quarter.
• Across five years, Non-Current Assets topped out at $31.2 million in Q1 2022 and bottomed at $9.6 million in Q2 2026.
• Historically, Non-Current Assets has averaged $22.4 million across 5 years, with a median of $23.5 million in 2024.
• The sharpest annual moves came in 2022 and 2026: Non-Current Assets jumped 95.94% in 2022, then slumped 51.59% in 2026.
• Over 5 years, Non-Current Assets stood at $28.5 million in 2022, then retreated by 14.07% to $24.5 million in 2023, then decreased by 12.51% to $21.5 million in 2024, then slumped by 50.75% to $10.6 million in 2025, then declined by 8.85% to $9.6 million in 2026.
• According to Business Quant data, Non-Current Assets over the past three periods registered $9.6 million, $10.0 million, and $10.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.